When considering the testosterone replacement therapy, careful attention to exclude the patients with breast or prostate cancer, high prostate-specific antigen (PSA) levels, hematocrit > 50%, untreated obstructive sleep apnea, and poorly controlled heart failure [40]. Here, KLK3 is linked to prostate carcinoma.